By Professor Ric Day

Journal articles

Stojanova J; Murnion B; Burrows F; Carlos L; Mizuno T; Nadai T; Irie K; Helsby N; Muthiah K; Day R, 2026, 'Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report', Pharmacotherapy, 46, http://dx.doi.org/10.1002/phar.70150

Flanagan P; Underwood M; Day RO; Machado G, 2026, 'Ending routine opioid use for acute non-specific back pain', American Journal of Emergency Medicine, 104, pp. 193 - 194, http://dx.doi.org/10.1016/j.ajem.2026.02.031

Crisp L; Day R; Shutt A; Briggs J; Pulver L, 2026, 'Achieving effective medicines governance: guiding principles for the roles and responsibilities of Medicines and Therapeutics Committees in Australian hospitals', Internal Medicine Journal, 56, pp. 888 - 892, http://dx.doi.org/10.1111/imj.70404

Abouelella A; Najah Q; Day RO; Arendt-Nielsen L; Lopez-Olivo MA; Bagg MK; Seah KTM; Alhasan M; Hamoudah A; Abuzied O; Al-tamimi M; Ibrahim A; Basheer E; Mahgoub R; Elhadi M, 2026, 'Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysis', Drugs, 86, pp. 719 - 736, http://dx.doi.org/10.1007/s40265-026-02304-2

Razmovski-Naumovski V; Chan DKE; Dubbai H; Day R, 2026, 'Examining the Auckland individualism–Collectivism scale in an Australian sample of community pharmacists', Journal of the American Pharmacists Association, 66, http://dx.doi.org/10.1016/j.japh.2026.103065

Mathieson S; Zadro JR; Narayan SW; McLachlan AJ; Ballantyne JC; Blyth FM; Day RO; Maher CG; McLachlan H; Lin CWC; Kamper SJ; Abdel Shaheed C, 2026, 'Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses', Drugs, 86, pp. 533 - 550, http://dx.doi.org/10.1007/s40265-026-02284-3

Stojanova J; Choy EBK; Brett J; Carland JE; Malek N; Day RO; Murnion B, 2026, 'Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non-Prescription Drug Assessment Unit', British Journal of Clinical Pharmacology, 92, pp. 1204 - 1212, http://dx.doi.org/10.1002/bcp.70366

Mumford V; Raban MR; Fitzpatrick E; Woods A; Merchant A; Badgery-Parker T; Li L; Gates P; Day RO; Ambler G; Dalla-Pozza L; Gazarian M; Gardo A; Barclay P; White L; Westbrook JI, 2026, 'Harm to Children from Prescribing and Administration Errors in Acute Care: A Multidisciplinary Panel Assessment', Drug Safety, 49, pp. 367 - 379, http://dx.doi.org/10.1007/s40264-025-01618-6

Stojanova J; Brett J; Murnion B; Day RO, 2026, 'Recent Medicare rebates for key pharmacogenomic tests: advancing equitable access to prevent serious drug reactions', Internal Medicine Journal, 56, pp. 335 - 341, http://dx.doi.org/10.1111/imj.70384

Yang Z; MP Jones C; Billot L; Devaux A; Shan S; Day RO; Hamilton M; Koes B; Latimer J; Maher CG; McLachlan AJ; McLachlan H; Webb M; Lin CWC, 2026, 'Oxycodone/naloxone versus placebo for acute spinal pain in compliant participants: secondary analysis of a randomised clinical trial', British Journal of Anaesthesia, 136, pp. 618 - 626, http://dx.doi.org/10.1016/j.bja.2025.10.019

Carland JE; Nguyen Y; Paul H; Ezard N; Bode M; Jagarlamudi B; Sandrasegaran M; Murnion B; Day RO; Preisz PT; Huber J; Brett J, 2026, 'A 3-year experience of an Australian short-stay Psychiatric, Alcohol and Non-prescription Drug Assessment Unit: unit activity and the patient experience', Emergency Medicine Journal, 43, pp. 15 - 21, http://dx.doi.org/10.1136/emermed-2024-214653

Gracé J; Connor DE; Day RO; Bucknall MP; Jenner A; Kocic D; Exner T; Parsi K, 2026, 'Formaldehyde is released from cyanoacrylate adhesives used in venous occlusion systems', Phlebology, http://dx.doi.org/10.1177/02683555261416665

Yiu CH; Ianni BD; Day RO; Raubenheimer J; Lu CY, 2026, 'Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme', Clinical Pharmacology and Therapeutics, http://dx.doi.org/10.1002/cpt.70334

Lin CWC; Maher CG; Day RO, 2025, 'Caution on the use of α2δ-ligands in neuropathic pain', Lancet Neurology, 24, pp. 993, http://dx.doi.org/10.1016/S1474-4422(25)00383-7

Yiu CH; Yau GTY; Wong ZH; Lin CY; Day RO; Raubenheimer J; Lu CY, 2025, 'Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence', International Journal of Clinical Pharmacy, 47, pp. 1567 - 1579, http://dx.doi.org/10.1007/s11096-025-01956-6

Baysari MT; Hilmer SN; Day RO; Van Dort BA; Zheng WY; Quirk R; Deidun D; Moran M; Stanceski K; Aryal N; Salem AA; Farrow L; Baker J; Hargreaves A; Grant J; Doherty P; Mekhail KZS; Westbrook JI; Li L, 2025, 'Effectiveness of computerised alerts to reduce drug–drug interactions (DDIs) and DDI-related harm in hospitalised patients: a quasi-experimental controlled pre–post study', BMJ Quality and Safety, 34, pp. 788 - 797, http://dx.doi.org/10.1136/bmjqs-2024-018243

Chaudhri K; Liu H; Rodgers A; Day R; Atkins ER; Gnanenthiran SR, 2025, 'Patients' and providers' perspectives of a dose administration aid strategy to improve cardiovascular disease prevention in Australian primary healthcare', BMC Health Services Research, 25, http://dx.doi.org/10.1186/s12913-025-12391-8

Yiu CH; Ianni BD; Day RO; Raubenheimer J; Lu CY, 2025, 'Treatment Persistence in Rheumatoid Arthritis Before and After Etanercept Biosimilar Introduction: A Nationwide Australian Real-World Study', Pharmaceutical Medicine, 39, pp. 369 - 381, http://dx.doi.org/10.1007/s40290-025-00577-8

de Oliveira Costa J; Lin J; Milder TY; Havard A; Greenfield JR; Day RO; Neuen BL; Gibson AA; Morton JI; Sacre JW; Pearson SA; Falster MO, 2025, 'Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk', European Journal of Clinical Pharmacology, 81, pp. 1315 - 1327, http://dx.doi.org/10.1007/s00228-025-03870-2

Browne E; Fairhall J; Day R, 2025, 'Argyria resulting from colloidal silver ingestion, a differential in modern-day practice', Internal Medicine Journal, 55, pp. 1410 - 1411, http://dx.doi.org/10.1111/imj.70163

MILDER TY; SHEPHERD L; PEARSON S-A; KRISTIAN RÅKET H; GREENFIELD J; DAY RO; LIN J; POLLOCK CA; NEUEN B; JUN MIN; DE OLIVEIRA COSTA J; STOCKER S; LUDINGTON J; FALSTER MO, 2025, '904-P: Hospitalization Is a Risk Factor for SGLT2i Discontinuation', Diabetes, 74, http://dx.doi.org/10.2337/db25-904-p

Lin J; Milder TY; Deakin CT; de Oliveira Costa J; Havard A; Neuen BL; Buckley NA; Brieger D; Greenfield JR; Jun M; Day RO; Pearson SA; Falster MO, 2025, 'Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study', Diabetes Research and Clinical Practice, 224, pp. 112242, http://dx.doi.org/10.1016/j.diabres.2025.112242

Mashuri YA; Hasanah M; Rahayu ID; Liverani M; Probandari A; Batura N; Schierhout G; Ferdiana A; Wulandari LPL; Dewi BK; Jan S; Yeung S; Wiseman V; Day R; Wibawa T, 2025, 'Post-market quality assessment of antibiotics: Findings from a cross-sectional study using standardised patients in Tabalong and Bekasi districts, Indonesia', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-087801

Stanceski K; Van Dort BA; Lee T; McLachlan AJ; Day RO; Hilmer SN; Li L; Westbrook J; Zheng WY; Barras M; Mekhail KZS; Baysari MT, 2025, 'Facilitators and Barriers to Uptake of Drug-Drug Interaction Alerts: Perspectives of Australian End Users and Managers', Applied Clinical Informatics, 16, pp. 295 - 304, http://dx.doi.org/10.1055/a-2481-4221

Stojanova J; Helsby NA; Wright DFB; Murnion B; Day RO, 2025, 'Alternative splicing with CYP3A4*22: Implications for the steroid-tacrolimus drug interaction', British Journal of Clinical Pharmacology, 91, pp. 1283 - 1284, http://dx.doi.org/10.1002/bcp.70029

Chaudhri K; Gnanenthiran SR; Williams A; Kearney M; Day RO; Rodgers A; Atkins ER, 2025, 'Effect of dose administration aids on adherence of self-administered medications: a systematic review', Journal of Pharmacy Practice and Research, 55, pp. 90 - 101, http://dx.doi.org/10.1002/jppr.1962

Milder TY; Lin J; Pearson SA; de Oliveira Costa J; Neuen BL; Pollock C; Jun M; Greenfield JR; Day RO; Stocker SL; Brieger D; Falster MO, 2025, 'Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?', Diabetes Obesity and Metabolism, 27, pp. 997 - 1000, http://dx.doi.org/10.1111/dom.16061

Yiu CH; Or CH; Almutairi K; Raubenheimer J; Day RO; Lu CY, 2025, 'Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials', Expert Opinion on Biological Therapy, 25, pp. 761 - 771, http://dx.doi.org/10.1080/14712598.2025.2512126

Selvadurai D; Coleshill MJ; Day RO; Briggs NE; Schulz M; Aung E, 2025, 'Health outcomes associated with patient-perceived gout aetiology: a cross-sectional analysis of the GAPP Study baseline data', Clinical Rheumatology, http://dx.doi.org/10.1007/s10067-025-07783-4

Knock E; Siefried KJ; Bedi G; Albert S; Day RO; Ezard N; Ross M; Liknaitzky P; Brett J, 2025, 'Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study', Addiction, http://dx.doi.org/10.1111/add.70187

White-Koning M; Wright DFB; Hughes DA; Michael TJF; Coleshill MJ; Aslani P; Day RO; Stocker SL, 2025, 'Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study', Clinical Pharmacokinetics, 64, pp. 93 - 105, http://dx.doi.org/10.1007/s40262-024-01467-z

Carland JE; Connor D; Starr M; Kocic D; Laba TL; Kevin RC; Stojanova J; Cunningham P; Day RO; Merlin K; Shiner CT, 2025, 'The economic evidence for microsampling to support therapeutic drug monitoring: A systematic review', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1002/bcp.70338

Milder TY; Lin J; Pearson SA; Greenfield JR; Day RO; Stocker SL; Neuen BL; Falster MO; de Oliveira Costa J, 2025, 'Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022', British Journal of Clinical Pharmacology, 91, pp. 117 - 126, http://dx.doi.org/10.1111/bcp.16231

McLachlan H; Maher CG; Lin CWC; Billot L; Day RO; Ivers R; Underwood M; McLachlan AJ; Richards B; Finnerup NB; Ferreira GE, 2024, 'DREAM: an adaptive, randomised, placebo-controlled trial of duloxetine for reducing leg pain in people with chronic sciatica - trial protocol', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2024-096796

Ferdiana A; Mashuri YA; Wulandari LPL; Rahayu ID; Hasanah M; Ayuningsih Z; Batura N; Khan M; Liverani M; Guy R; Schierhout G; Kaldor J; Law M; Day R; Jan S; Wibawa T; Probandari A; Yeung S; Wiseman V, 2024, 'The impact of a multi-faceted intervention on non-prescription dispensing of antibiotics by urban community pharmacies in Indonesia: a mixed methods evaluation', BMJ Global Health, 9, http://dx.doi.org/10.1136/bmjgh-2024-015620

Shen I; Stojanova J; Yeo M; Olsen N; Lockart I; Wang M; Roggeveld J; Heerspink HJL; Greenfield JR; Day R; Danta M, 2024, 'A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease', British Journal of Clinical Pharmacology, 90, pp. 2529 - 2538, http://dx.doi.org/10.1111/bcp.16139

Carland JE; Carland DJ; Brett J; Stocker SL; Roberts DM; Day RO; Laba TL, 2024, 'Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review', British Journal of Clinical Pharmacology, 90, pp. 2038 - 2066, http://dx.doi.org/10.1111/bcp.16164

Schulz M; Day RO; Coleshill MJ; Briggs NE; Aung E, 2024, 'Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout', Clinical Rheumatology, 43, pp. 2943 - 2954, http://dx.doi.org/10.1007/s10067-024-07050-y

Wabe N; Huang G; Silva SM; Nguyen AD; Seaman K; Raban MZ; Gates P; Day R; Close JCT; Lord SR; Westbrook JI, 2024, 'A Longitudinal Study of the Use and Effects of Fall-Risk-Increasing Drugs in Residential Aged Care', Journal of the American Medical Directors Association, 25, pp. 105074, http://dx.doi.org/10.1016/j.jamda.2024.105074

Kirubakaran R; Singh RM; Carland JE; Day RO; Stocker SL, 2024, 'Evaluation of Published Population Pharmacokinetic Models to Inform Tacrolimus Therapy in Adult Lung Transplant Recipients', Therapeutic Drug Monitoring, 46, pp. 434 - 445, http://dx.doi.org/10.1097/FTD.0000000000001210

Mumford V; Raban MZ; Li L; Fitzpatrick E; Woods A; Merchant A; Badgery-Parker T; Gates P; Baysari M; Day RO; Ambler G; Dalla-Pozza L; Gazarian M; Gardo A; Barclay P; White L; Westbrook JI, 2024, 'Developing a process to measure actual harm from medication errors in paediatric inpatients: From design to implementation', British Journal of Clinical Pharmacology, 90, pp. 1615 - 1626, http://dx.doi.org/10.1111/bcp.16052

de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597

Selvadurai D; Coleshill MJ; Day RO; Briggs NE; Schulz M; Reath J; Aung E, 2024, 'Patient factors and health outcomes associated with illness perceptions in people with gout', Rheumatology United Kingdom, 63, pp. 1927 - 1937, http://dx.doi.org/10.1093/rheumatology/kead501

Michael TJF; Wright DFB; Chan JS; Coleshill MJ; Aslani P; Hughes DA; Day RO; Stocker SL, 2024, 'Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study', Acr Open Rheumatology, 6, pp. 403 - 411, http://dx.doi.org/10.1002/acr2.11666

Carland JE; Stojanova J; Lau C; Day RO; Marriott DJE, 2024, 'Crying Over Stark Differences: Resource Disparity and Therapeutic Drug Monitoring', Therapeutic Drug Monitoring, 46, pp. 415 - 416, http://dx.doi.org/10.1097/FTD.0000000000001185

Li L; Baker J; Quirk R; Deidun D; Moran M; Salem AA; Aryal N; Van Dort BA; Zheng WY; Hargreaves A; Doherty P; Hilmer SN; Day RO; Westbrook JI; Baysari MT, 2024, 'Drug–Drug Interactions and Actual Harm to Hospitalized Patients: A Multicentre Study Examining the Prevalence Pre- and Post-Electronic Medication System Implementation', Drug Safety, 47, pp. 557 - 569, http://dx.doi.org/10.1007/s40264-024-01412-w

Jones CMP; Day RO; Koes BW; Latimer J; Maher CG; McLachlan AJ; Billot L; Shan S; Lin CWC, 2024, 'Opioids for back and neck pain: the OPAL trial – Authors' reply', Lancet, 403, pp. 2379 - 2380, http://dx.doi.org/10.1016/S0140-6736(24)00487-2

Michael TJF; Chan JS; Hughes S; Wright DFB; Coleshill MJ; Hughes DA; Day RO; Aslani P; Stocker SL, 2024, 'The experiences and perspectives of people with gout on urate self-monitoring', Health Expectations, 27, http://dx.doi.org/10.1111/hex.14071

Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E, 2024, 'Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing', British Journal of Clinical Pharmacology, 90, pp. 1322 - 1332, http://dx.doi.org/10.1111/bcp.16016

Gilanyi YL; Shah B; Cashin AG; Gibbs MT; Bellamy J; Day R; McAuley JH; Jones MD; McAuley J; Bellamy J; Gibbs M, 2024, 'Barriers and enablers to exercise adherence in people with nonspecific chronic low back pain: a systematic review of qualitative evidence.', Pain, 165, pp. 2200 - 2214, http://dx.doi.org/10.1097/j.pain.0000000000003234

Back to profile page